Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATryn in Postcardiotomy ECMO Patients
NCT03090893Phase 1Withdrawn
- Sponsor
- Mayo Clinic
- Start
- Jun 2018
- Primary completion
- Jun 2019
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 1, open-label, single-arm trial of antithrombin III in Antithrombin deficiency (ATD), sponsored by Mayo Clinic. Primary endpoint: Percentage of time within the serum AT level target range of 80-100% at 72 hours. Planned start Jun 2018; status: withdrawn.
02
Drugs
antithrombin III
03
Conditions
Antithrombin deficiency (ATD)
Beyond the preview
Go deeper on NCT03090893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03090893.